United Therapeutics Corporation to present 12 new data presentations at ATS 2026 Conference
United Therapeutics Corporation announced that 12 new data presentations across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference, May 15-20, in Orlando.
“We are thrilled to share additional positive data from the TETON-1 study in IPF and the ADVANCE OUTCOMES study in PAH, our pivotal studies that achieved unprecedented results in these two life-threatening diseases that have significant unmet needs. The data we are sharing from our research programs in pulmonary hypertension and ILD, including PHINDER, ARTISAN, and TETON-PPF, will also provide important clinical insights that may meaningfully impact how these devastating diseases are managed and help improve outcomes for the people living with them,” – Andrew Nelsen, PharmD, Vice President, Global Medical Affairs at United Therapeutics.
Poster Presentations Include:
ARTISAN Interim Analysis: Early Treatment with High-Dose Treprostinil Reduces Mean Pulmonary Artery Pressure and Improves Risk Status in Pulmonary Arterial Hypertension, Oral Session AQ19, Sunday, May 17, 9:27 – 9:39 am
Patient Insights into Subcutaneous Pump Therapy in Pulmonary Arterial Hypertension, Poster Session A65, Sunday, May 17, 11:30 am – 1:15 pm
Accuracy of Clinician Suspicion for Pulmonary Hypertension in Interstitial Lung Disease by Care Setting: Interim Comparison from the PHINDER Study,Poster Session B41,Monday, May 18, 11:30 am – 1:15 pm
Real-world Dosing of Parenteral Treprostinil Post-Sotatercept Launch, Poster Session B67, Monday, May 18, 11:30 am – 1:15 pm
Real-World Persistence to Oral Treprostinil in Patients with Pulmonary Arterial Hypertension: A Decade in Review, Poster Session B106, Monday, May 18, 2:15 pm – 4:15 pm
TETON Phase 3 Clinical Trials of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis: Integrated Efficacy and Safety Results for TETON-1 and TETON-2, Mini-Symposium B95, Monday, May 18, 3:51 pm – 4:03 pm
Clinical Outcomes with Parenteral Induction Therapy in Patients with Methamphetamine-Associated PAH: A Subgroup Analysis of the EXPEDITE Study,Poster Session C65, Tuesday, May 19, 11:30 am – 1:15 pm
Patient Reported Outcomes in Interstitial Lung Disease with and without Pulmonary Hypertension: Interim Results from the PHINDER Study, Poster Session C104, Tuesday, May 19, 2:15 pm – 4:15 pm
TETON-1 Phase 3 Clinical Trial of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis, Poster Session C103, Tuesday, May 19, 2:15 pm – 4:15 pm
TETON-PPF Clinical Trial of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis, Poster Session C103, Tuesday, May 19, 2:15 pm – 4:15 pm
ADVANCE OUTCOMES: A Phase 3, Double-Blind, Placebo-Controlled Clinical Trial of Ralinepag for the Treatment of Pulmonary Arterial Hypertension, Poster Session D28, Wednesday, May 20, 8:15 am – 10:15 am
Real-World Comparison of Antifibrotic-Treated and Untreated Patients with Idiopathic Pulmonary Fibrosis in a Commercial and Medicare Advantage Population, Poster Session D22, Wednesday, May 20, 8:15 am – 10:15 am
